Vascular endothelial growth factor (VEGF) is considered to play an es sential role in the pathogenesis of age-relatedma- cular degeneration due to its vascular permeability-inducing and angiogenic p roperties. Ranibiz...Vascular endothelial growth factor (VEGF) is considered to play an es sential role in the pathogenesis of age-relatedma- cular degeneration due to its vascular permeability-inducing and angiogenic p roperties. Ranibizumab, a small antibody fragment designed to competitively bind all VEGF isoforms, passes after intravitreal injection all retinal layers reach ing the retinal pigment epithelium-choroid complex. Experimental animal models showed the drug to be safe and effective. Subsequently, Phase I/II clinical tria ls conducted in patients with neovascular AMDdemonstrated a good safety profile, and a significant functional benefit. Ranibizumab therapy repeated every four we eks for the treatment of neovascular AMD is currently in Phase III clinical tria ls. Combination therapy trials aiming for improved treatment durability and effe ctiveness are currently ongoing as well as new treatment strategies using interm ittent, optical coherence tomography (OCT) guided therapy. Anti-VEGF therapy us ingRanibizumab is a promising newtreatment option for neovascular AMD.展开更多
文摘Vascular endothelial growth factor (VEGF) is considered to play an es sential role in the pathogenesis of age-relatedma- cular degeneration due to its vascular permeability-inducing and angiogenic p roperties. Ranibizumab, a small antibody fragment designed to competitively bind all VEGF isoforms, passes after intravitreal injection all retinal layers reach ing the retinal pigment epithelium-choroid complex. Experimental animal models showed the drug to be safe and effective. Subsequently, Phase I/II clinical tria ls conducted in patients with neovascular AMDdemonstrated a good safety profile, and a significant functional benefit. Ranibizumab therapy repeated every four we eks for the treatment of neovascular AMD is currently in Phase III clinical tria ls. Combination therapy trials aiming for improved treatment durability and effe ctiveness are currently ongoing as well as new treatment strategies using interm ittent, optical coherence tomography (OCT) guided therapy. Anti-VEGF therapy us ingRanibizumab is a promising newtreatment option for neovascular AMD.
